Trials / Completed
CompletedNCT01915784
Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD
Study Evaluating Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Preference study: Genuair® (Pressair™) vs Breezhaler® (Neohaler™) inhalers in patients with COPD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Genuair® | Inhaler with placebo only. Once daily, for 14 days. |
| DEVICE | Breezhaler® | Inhaler with placebo only. Once daily, for 14 days. |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2013-08-05
- Last updated
- 2015-05-29
Locations
6 sites across 3 countries: Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01915784. Inclusion in this directory is not an endorsement.